Topiramate and the vision: a systematic review
- PMID: 22275816
- PMCID: PMC3261698
- DOI: 10.2147/OPTH.S27695
Topiramate and the vision: a systematic review
Abstract
Background and purpose: Topiramate (TPM) is a sulfa-derivative monosaccharide that is used mainly for treating epilepsy and preventing migraine. Within the gamut of side effects attributable to this drug, ophthalmologic manifestations are of crucial importance. In this study, for the first time, the aim was to provide a systematic literature review regarding this issue.
Methods: For the time period 1996-2011, a PubMed search was made for the studies concerning the adverse/beneficial effects of TPM on vision. Overall, 404 citations out of a total of 2756 TPM-related studies were examined for relevance.
Results: A total of 74 relevant studies were reviewed, 65 of which comprise small observational studies describing the ophthalmic side effects of TPM in 84 patients. Of these patients, 66 were affected by ciliochoroidal effusion syndrome as the cardinal ocular side effect of TPM (17 cases of myopic shift and 49 cases of angle closure glaucoma). A comprehensive statistical analysis is provided on these 66 subjects. Other rare side effects of TPM on the vision were also reviewed, including massive choroidal effusion, ocular inflammatory reactions, visual field defects, probable effects on retina, cornea, and sclera, and neuroophthalmologic complications. In addition, a framework is provided to classify these results.
Discussion: Due to the expanding spectrum of indications for the administration of TPM, neurologists and psychiatrists should be aware of its diverse ocular side effects. In conclusion, ocular complications following this drug should be taken seriously and be subjected to ophthalmic counseling.
Keywords: eye; ophthalmology; review; side effect; topiramate; vision.
Similar articles
-
The Ophthalmic Side Effects of Topiramate: A Review.Cureus. 2022 Aug 28;14(8):e28513. doi: 10.7759/cureus.28513. eCollection 2022 Aug. Cureus. 2022. PMID: 36059357 Free PMC article. Review.
-
Topiramate-induced ocular complications: case series.Rom J Ophthalmol. 2024 Jan-Mar;68(1):72-74. doi: 10.22336/rjo.2024.14. Rom J Ophthalmol. 2024. PMID: 38617722 Free PMC article.
-
Evaluation of Ocular Side Effects in the Patients on Topiramate Therapy for Control of Migrainous Headache.J Clin Diagn Res. 2016 Mar;10(3):NC01-4. doi: 10.7860/JCDR/2016/16263.7339. Epub 2016 Mar 1. J Clin Diagn Res. 2016. PMID: 27134906 Free PMC article.
-
Topiramate induced bilateral hypopyon uveitis and choroidal detachment: a report of two cases and review of literature.BMC Ophthalmol. 2021 Jul 27;21(1):287. doi: 10.1186/s12886-021-02050-x. BMC Ophthalmol. 2021. PMID: 34315425 Free PMC article. Review.
-
The Use of Topiramate for Weight Loss Causing Acute Glaucoma: A Case Report and Literature Review.Med Hypothesis Discov Innov Ophthalmol. 2019 Summer;8(2):116-120. Med Hypothesis Discov Innov Ophthalmol. 2019. PMID: 31263722 Free PMC article.
Cited by
-
Angiographic features of drug-induced bilateral angle closure and transient myopia with Ciliochoroidal effusion.BMC Ophthalmol. 2019 Nov 4;19(1):213. doi: 10.1186/s12886-019-1230-y. BMC Ophthalmol. 2019. PMID: 31684898 Free PMC article.
-
Traumatic myopia secondary to ciliary spasm after blunt eye trauma and reconsideration of its pathogenesis.Graefes Arch Clin Exp Ophthalmol. 2016 Jul;254(7):1411-7. doi: 10.1007/s00417-016-3282-5. Epub 2016 Feb 10. Graefes Arch Clin Exp Ophthalmol. 2016. PMID: 26860527
-
Effectiveness of Topiramate Versus Acetazolamide in the Management of Idiopathic Intracranial Hypertension: ASystematic Review and Meta-Analysis.Medicina (Kaunas). 2025 Mar 4;61(3):450. doi: 10.3390/medicina61030450. Medicina (Kaunas). 2025. PMID: 40142261 Free PMC article.
-
Use of Visual Electrophysiology to Monitor Retinal and Optic Nerve Toxicity.Biomolecules. 2022 Sep 29;12(10):1390. doi: 10.3390/biom12101390. Biomolecules. 2022. PMID: 36291599 Free PMC article. Review.
-
Swallow-Induced Eyelid Myokymia: A Novel Synkinesis Syndrome.Neuroophthalmology. 2019 Apr 1;44(2):108-110. doi: 10.1080/01658107.2019.1587637. eCollection 2020 Apr. Neuroophthalmology. 2019. PMID: 32395158 Free PMC article.
References
-
- Angehagen M, Ronnback L, Hansson E, Ben-Menachem E. Topiramate reduces AMPA-induced Ca(2+) transients and inhibits GluR1 subunit phosphorylation in astrocytes from primary cultures. J Neurochem. 2005;94(4):1124–1130. - PubMed
-
- Panday VA, Rhee DJ. Review of sulfonamide-induced acute myopia and acute bilateral angle-closure glaucoma. Compr Ophthalmol Update. 2007;8(5):271–276. - PubMed
-
- Mirza NS, Alfirevic A, Jorgensen A, Marson AG, Pirmohamed M. Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors. Pharmacogenet Genomics. 2011;21(5):297–302. - PubMed
-
- United States Food and Drug Administration; Ortho-McNeil Pharmaceutical Inc. FDA approved labeling text. 2011. [Accessed August 27, 2011]. Available from: www.fda.gov/downloads/Drugs/DrugSafety/UCM152837.pdf.
-
- Christensen J, Hojskov CS, Dam M, Poulsen JH. Plasma concentration of topiramate correlates with cerebrospinal fluid concentration. Ther Drug Monit. 2001;23(5):529–535. - PubMed
LinkOut - more resources
Full Text Sources